People with MS can also take other medications for symptoms, complications, and relapses. Multiple sclerosis (MS) causes neurological symptoms that typically worsen over time. People with MS ...

Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide following dangerous brain inflammation in seven patients in Europe.

came under fire for delaying its decision on whether the breakthrough drug beta interferon should be available to all MS sufferers on the NHS. Catherine, who had to fight for her right to have the ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Prenatal and early life sun exposure is associated with a lower risk for relapse in childhood-onset MS, new findings suggest, ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...